• Publications
  • Influence
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4
It is suggested that manipulation of SDF-1–CXCR4 interactions may be a means with which to control the navigation of progenitors between the BM and blood to improve the outcome of clinical stem cell transplantation. Expand
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant
Preliminary data in 26 patients with standard indications for allogeneic BMT suggest that nonmyeloablative conditioning including fludarabine, anti-T-lymphocyte globulin, and low-dose busulfan is extremely well tolerated, with no severe procedure-related toxicity. Expand
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.
Up-regulation of CXCR4 expression may be useful for improving engraftment of repopulating stem cells in clinical transplantation. Expand
Comparative studies of human FcRIII-positive and negative natural killer cells.
Three subpopulations of peripheral blood NK cells based on the surface expression of CD56 and CD16 are identified and proposed that these NK cell subsets represent portions of the NK cell differentiation pathway present in the peripheral blood. Expand
Autologous transplantation and maintenance therapy in multiple myeloma.
Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as compared with MPR, significantly prolonged progression-free and overall survival among patients with multiple myeloma who were 65 years of age or younger. Expand
The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice.
It is demonstrated that repopulating human stem cells functionally express LFA-1, VLA-4, andVLA-5, and this study implies a novel approach to further advance clinical transplantation. Expand
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international
PD-1 blockade after AHSCT using pidilizumab may represent a promising therapeutic strategy in this disease, and this is the first demonstration of clinical activity of PD- 1 blockade in DLBCL. Expand
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12‐triggered integrin activation but not in chemokine‐triggered motility of human T lymphocytes and CD34+ cells
It is reported that CXCR7 fails to support on its own any CXCL12‐triggered integrin activation or motility in human T lymphocytes or CD34+ progenitors, and its blocking can be useful for therapeutic interference with CX CR4‐mediated activation of integrins. Expand
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
Purpose: CT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. TheExpand
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.
Hematopoietic stem cells rarely contribute to hepatic regeneration, however, the mechanisms governing their homing to the liver, which is a crucial first step, are poorly understood. The chemokineExpand